Danaher (NYSE:DHR) Given New $255.00 Price Target at Morgan Stanley

Danaher (NYSE:DHR) had its price target decreased by Morgan Stanley from $270.00 to $255.00 in a report released on Wednesday morning,MarketScreener reports.

Other equities analysts also recently issued reports about the stock. Leerink Partners boosted their target price on shares of Danaher from $260.00 to $270.00 and gave the stock an “outperform” rating in a research note on Friday, January 16th. Rothschild & Co Redburn set a $205.00 price target on shares of Danaher in a research report on Friday, April 17th. Guggenheim lowered their price target on shares of Danaher from $275.00 to $235.00 and set a “buy” rating for the company in a research report on Wednesday. Jefferies Financial Group reiterated a “buy” rating and set a $245.00 price target on shares of Danaher in a research report on Tuesday. Finally, Wolfe Research lowered their price target on shares of Danaher from $260.00 to $230.00 and set an “outperform” rating for the company in a research report on Wednesday, April 8th. Seventeen research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Danaher has a consensus rating of “Moderate Buy” and an average price target of $242.45.

Danaher Price Performance

Shares of NYSE DHR traded down $7.19 during trading on Wednesday, reaching $176.85. The company had a trading volume of 2,293,837 shares, compared to its average volume of 4,080,369. Danaher has a 52 week low of $176.00 and a 52 week high of $242.80. The stock has a market cap of $125.16 billion, a PE ratio of 34.23, a PEG ratio of 2.64 and a beta of 0.95. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.51 and a current ratio of 1.87. The business’s 50 day moving average price is $197.17 and its 200-day moving average price is $214.35.

Danaher (NYSE:DHR) last announced its earnings results on Tuesday, April 21st. The conglomerate reported $2.06 earnings per share for the quarter, topping analysts’ consensus estimates of $1.94 by $0.12. Danaher had a net margin of 14.89% and a return on equity of 10.96%. The company had revenue of $5.95 billion during the quarter, compared to the consensus estimate of $6 billion. During the same period in the previous year, the firm posted $1.88 earnings per share. The company’s revenue was up 3.7% on a year-over-year basis. Danaher has set its FY 2026 guidance at 8.350-8.550 EPS. Analysts expect that Danaher will post 8.39 earnings per share for the current year.

Danaher Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, April 24th. Stockholders of record on Friday, March 27th will be given a dividend of $0.40 per share. The ex-dividend date is Friday, March 27th. This represents a $1.60 annualized dividend and a dividend yield of 0.9%. This is a positive change from Danaher’s previous quarterly dividend of $0.32. Danaher’s dividend payout ratio is presently 30.95%.

Insider Transactions at Danaher

In related news, EVP Gregory M. Milosevich sold 1,320 shares of the business’s stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $208.01, for a total transaction of $274,573.20. Following the completion of the transaction, the executive vice president owned 5,099 shares in the company, valued at approximately $1,060,642.99. The trade was a 20.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 10.80% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. JPL Wealth Management LLC acquired a new position in Danaher during the third quarter valued at approximately $25,000. Elevated Capital Advisors LLC acquired a new position in Danaher during the fourth quarter valued at approximately $26,000. WFA of San Diego LLC acquired a new position in Danaher during the second quarter valued at approximately $26,000. ANTIPODES PARTNERS Ltd bought a new position in Danaher in the third quarter valued at approximately $27,000. Finally, Hilton Head Capital Partners LLC bought a new position in Danaher in the fourth quarter valued at approximately $27,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Key Danaher News

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Q1 EPS beat and slight full‑year EPS raise: Danaher reported $2.06 non‑GAAP EPS (ahead of estimates) and nudged FY‑2026 adjusted EPS guidance to a range that was only modestly higher, supporting the view of durable profitability. Read More.
• Positive Sentiment: Analyst support from Evercore: Evercore raised its price target (to $232) and maintained an outperform stance, providing some buy‑side reinforcement amid the downdraft. Read More.
• Neutral Sentiment: Large euro‑note offering announced: Danaher priced ~€3.0B net of proceeds in four tranches (2028–2038 maturities). The deal boosts liquidity but increases gross debt on the balance sheet while funding corporate needs (including M&A). Read More.
• Neutral Sentiment: Bioprocessing strength vs. mixed start: Management highlighted bioprocessing momentum and acquisition strategy, which helped headline growth, but the quarter showed mixed signals across segments. Read More.
• Negative Sentiment: Revenue miss and Diagnostics softness: Revenue rose ~3.7% Y/Y but missed consensus; core revenue growth was modest and Diagnostics saw weakness (lighter respiratory season at Cepheid), which worried investors despite the EPS beat. Read More.
• Negative Sentiment: Multiple price‑target cuts: Several firms trimmed targets (JPMorgan, UBS, Guggenheim, Wells Fargo, TD Cowen among others), which can prompt headline selling and reduce near‑term upside expectations. Read More. Read More. Read More.
• Negative Sentiment: Market concern about Masimo deal & capital allocation: Commentators flagged near‑term uncertainty around integration, capital allocation and how incremental spending/financing (including the euro notes) will affect returns, adding to investor caution. Read More.
• Negative Sentiment: Insider selling & repositioning by institutions: Reports of recent insider sales and large institutional rebalancing were cited in market coverage, which may have amplified downward pressure. Read More.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.